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Abstract
Background: Typical high throughput microarrays experiments compare gene expression across two
specimen classes – an experimental class and baseline (or comparison) class. The choice of specimen
classes is a major factor in the differential gene expression patterns revealed by these experiments. In most
studies of prostate cancer, histologically malignant tissue is chosen as the experimental class while normal
appearing prostate tissue adjacent to the tumor (adjacent normal) is chosen as the baseline against which
comparison is made. However, normal appearing prostate tissue from tumor free organ donors
represents an alterative source of baseline tissue for differential expression studies.
Methods: To examine the effect of using donor normal tissue as opposed to adjacent normal tissue as a
baseline for prostate cancer expression studies, we compared, using oligonucleotide microarrays, the
expression profiles of primary prostate cancer (tumor), adjacent normal tissue and normal tissue from
tumor free donors.
Results: Statistical analysis using Significance Analysis of Microarrays (SAM) demonstrates the presence
of unique gene expression profiles for each of these specimen classes. The tumor v donor expression
profile was more extensive that the tumor v adjacent normal profile. The differentially expressed gene lists
from tumor v donor, tumor v adjacent normal and adjacent normal v donor comparisons were examined
to identify regulated genes. When donors were used as the baseline, similar genes are highly regulated in
both tumor and adjacent normal tissue. Significantly, both tumor and adjacent normal tissue exhibit
significant up regulation of proliferation related genes including transcription factors, signal transducers
and growth regulators compared to donor tissue. These genes were not picked up in a direct comparison
of tumor and adjacent normal tissues.
Conclusions: The up-regulation of these gene types in both tissue types is an unexpected finding and
suggests that normal appearing prostate tissue can undergo genetic changes in response to or in
expectation of morphologic cancer. A possible field effect surrounding prostate cancers and the
implications of these findings for characterizing gene expression changes in prostate tumors are discussed.
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Background
Prostate cancer is the most common cancer in men result-
ing in over 30,000 deaths annually [1]. Early detection
and treatment has the potential to markedly reduce the
morbidity and mortality associated with the disease.
While elevated Prostate Specific Antigen (PSA) [2] is the
best available indicator of men with cancer [3], its diag-
nostic utility is limited due to elevated PSA levels in other
non-malignant prostate conditions, varying levels in
advanced disease and poor correlation between PSA levels
and extent of disease. Furthermore, the variable course of
prostate cancer – many patients will not die of the disease
– means that radical therapy for all early cases would
result in over treatment of significant number of patients.
High throughput genomic technologies, by simultane-
ously interrogating the expression levels of thousands of
genes, offers the potential to identify new biomarkers for
early detection, prognosis, targets for therapy and for
reclassification of prostate tumors. Using expression
microarrays, a number of studies have characterized
expression profiles for prostate cancer and other tumors.
In some cases, correlations between tumor expression sig-
natures, clinical parameters and outcome [4-12] have
been identified. While potentially powerful, such studies
can be significantly impacted by the choice of baseline or
"normal" tissue used to detect tumor related expression
changes. Most prostate expression studies to date have uti-
lized normal appearing tissue adjacent to tumor as the tis-
sue for comparison. However, a variety of methods such
as chromosomal analysis [13], SAGE [14] and ploidy
analysis [15,16] have shown molecular abnormalities in
normal appearing prostate adjacent to tumor. Even the
term "normal appearing" prostate tissue adjacent to
tumor may be misleading, as morphologic researchers
using quantitative imaging analysis [17-19], have identi-
fied morphologic changes in the epithelial nuclei and
blood vessels architecture in prostate tissue adjacent to
tumor that are not routinely commented upon by pathol-
ogists. This suggests that, in some cases, tissues adjacent to
cancer, although appearing morphologically normal by
traditional microscopic examination, may contain genetic
changes associated with the genesis of or reaction to can-
cer. Therefore, the use of adjacent normal as the baseline
tissue for comparative gene expression studies may mask
tumor related molecular changes preceding the appear-
ance of histological tumor. More recently, a microarray
study from our institution [12], using adjacent normal
and tumor samples, describes a potential field effect
around prostate cancers and regulation of selected genes
in both adjacent normals and tumors. Using the same
microarray data set for our analysis, we have compared
the gene expression profiles of prostate cancer, normal
appearing prostate tissue adjacent to tumor, and normal
appearing prostate tissue from cancer free tissue donors
with the aim of identifying the optimal baseline tissue for
expression studies and the gene expression changes
between the three specimen types.
Methods
Clinical profile of cases
The 60 tumor samples used in this study consisted of 2,
13, 27, 6 and 12 cases of primary prostatic adenocarci-
noma of Gleason grade 5, 6, 7, 8 and 9 respectively. There
were 4, 20, 23 and 13 cases spanning the age groups 40–
49, 50–59, 60–69 and 70–79 respectively. Of the cases, 36
were stage T3 or higher with 2, 22, 23, 11 and 2 cases of
stage T2a, T2b, T3a, T3b and 4 respectively.
The 63 adjacent normal samples consisted of 2, 11, 29, 8,
and 13 cases of Gleason grade 5, 6, 7, 8 and 9 respectively.
There were 4, 21, 25 and 12 cases spanning the age groups
40–49, 50–59, 60–69 and 70–79 respectively. There were
2, 21, 26, 12 and 2 cases of Stage T2a, T2b, T3a, T3b and
T4 respectively.
Of the donors, 11 are under and 7 are over the age of 40.
Samples and sample procurement
The tumor and adjacent normal tissue samples were
acquired from the University of Pittsburgh Medical Center
under stringent Institutional Review Board guidelines
with appropriate informed consent. Specimens were
received directly from the operating room. Samples (>500
mg) were excised and snap frozen in liquid nitrogen
within 30 min of excision and stored at -80°C in the Uni-
versity of Pittsburgh Pathology Tissue Bank until extrac-
tion of RNA. All samples were submitted for pathology
evaluation. In every case, the tissue was excised from the
junction between the ejaculatory duct and the prostatic
urethra in the transition zone of the prostate. In particular,
adjacent normal tissue was excised away from the cancer
lesion macroscopically, and their histological diagnosis
was confirmed microscopically.
Donor tissue specimens were received through a collabo-
rative arrangement with the Center for Organ Recovery
and Education (CORE), the local organ procurement
agency. The arrangement allows the University of Pitts-
burgh Pathology Tissue Bank to acquire normal prostates
and associated serum/plasma specimens from healthy
individuals who have donated their organs for transplant.
There is extensive collaborative support from CORE. The
donor prostatectomies harvested from brain dead, per-
fused donors and are bathed in Ringer's Lactate solution
and transported on wet ice. These donor prostates are
transported and handled with the harvested "transplant"
organs. This significantly reduces transit time and mini-
mizes the degradation of RNA. The processing methodol-
ogies used consist of snap freezing tissues in bulk, freezing
in OCT and processing the tissues for routine histologyBMC Cancer 2005, 5:45 http://www.biomedcentral.com/1471-2407/5/45
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(paraffin embedded tissues. For microarray analysis, the
donor samples were excised from the same zone as the
tumor and adjacent normal samples.
cRNA preparation and Affymetrix chip hybridization
cRNA was prepared and hybridized to Affymetrix oligonu-
cleotide arrays as previously described [12]
Statistical analysis
We analyzed prostate tissue samples from 18 donors and
63 prostate cancer patients. From the prostate cancer
patients we took samples from the histologic tumor as
well as normal appearing tissue adjacent to the tumor.
High quality RNA and chip data were obtained from 60
cancer and 63 adjacent to tumor samples. In total 141
samples were run against the Affymetrix U95A chip and
analyzed. The raw scanned array images were first proc-
essed through the Affymetrix Microarray Analysis Suite
5.0 (Affymetrix Corporation, Santa Clara, Ca) to generate
probe cel intensity (*.cel) files. The *.cel files were then
analyzed using both MAS 5.0 and dChip software from
Harvard University [20], to generate gene expression sig-
nal values for each probe set. Data normalization to
remove variation in overall chip intensities was perfumed
by global scaling to a chip mean target intensity of 200
(MAS 5.0) or by the rank-invariant method (dCHIP). The
MAS 5.0 with global scaling data and dChip with rank-
invariant normalization data gave similar results in the
subsequent analysis. Therefore, in the interests of clarity,
we will focus on the MAS 5.0 results in the remainder this
paper.
In the next phase of analysis, the donors, adjacent nor-
mals and tumors were compared for differences in gene
expression by using signal values for all 12625 probe sets
for each sample. For statistical analysis, we used the Sig-
nificance Analysis of Microarray (SAM) software package
from Stanford University [21]. This method was chosen
over conventional statistical tests because of its acceptance
in the microarray community, its general simplicity and
its ability to provide an estimate of the false discovery rate
(the ratio of false positives to total positives). The false
discovery rate is particularly important when comparing
the expression of thousands of genes simultaneously. For
example, when using the Student's t test at a P value of
0.05 to examine a population of 10,000 genes, one would
expect 500 false positives. If there were in fact 100 true
positives, the false positive rate would be an unacceptably
high 0.83 (500/600).
Briefly, SAM calculates a value for each probe set on the
array. This value represents the observed difference in
mean expression levels between the specimen classes
being compared (i.e. tumor and donor) divided by the
variance in the data and a fudge factor (see the original
paper for details [21]. The resulting value is called the
"observed d value". To determine the significance of this
value, SAM estimates the "expected" d value if there were
no difference between the specimen classes. This is done
by permutating (randomly changing) the class labels
without changing the data and recalculating the SAM
value for each probe set. After thousands of permutations,
the result estimates the value that would be obtained if the
difference in gene expression were due to chance alone.
This is the "expected d value".
The significance of the observed differential gene expres-
sion can be estimated by comparing the observed and
expected d values. A user defined threshold or "delta"
(observed d value – expected d value) can be adjusted to
select only those genes observed d value exceeds (for up
regulated genes) or is lower (for down regulated genes)
than delta. The greater the "delta", the greater the strin-
gency of the result and lower the false discovery rate. For
each delta value, the SAM output consists of a gene (probe
set) list and an associated false discovery rate. The false
discovery rate is estimated from the distribution of
expected and observed d values. Probe sets are ordered on
the basis of observed d value metric, probe sets with high
(or low) values represent genes with relatively high differ-
ential expression. The "SAM Plots" are also very useful in
visualizing differences in overall differential gene expres-
sion between specimen classes.
Results
Expression analysis of tumor, adjacent normal and donor 
tissue
The prostate tumors analyzed in this study consisted of
Gleason grades 5, 6, 7, 8, 9 and patients spanned the ages
of 40 through 79. The goal of our research was to examine
the differential gene expression patterns observed when
comparing our three specimen classes: tumor versus adja-
cent normal, tumor versus donor and adjacent normal
versus donor. The comparison was made at three points in
the analytical process: 1) after normalization to remove
variation in overall chip intensity 2) after statistical analy-
sis of the data and, 3) after examining the differentially
expressed gene lists.
To examine differences in normalized gene expression
between tumors, adjacent normals and donors the mean
MAS 5.0 and dChip generated signal of each probe set for
each specimen class (60 tumors, 63 adjacent normals and
19 donors), was calculated and plotted on a series of scat-
ter plots (Fig 1).
Figure 1 shows the scatter plots and Pearson correlations
of the normalized expression data analyzed using both
MAS 5.0 and dChip as described above (vide supra, Meth-
ods). Data scatter is maximum in the tumor versus donorBMC Cancer 2005, 5:45 http://www.biomedcentral.com/1471-2407/5/45
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comparison, intermediate in adjacent normal versus
donor and minimal in tumor versus adjacent normal.
These findings are suggestive of more differential gene
expression in tumor versus donor than tumor versus adja-
cent normal. In other words, donor normal tissue and
adjacent normal tissue do not show the same degree of
differential gene expression when paired with tumor tis-
sue. Another striking result apparent in Figure 1 is the
close correlation and limited scatter of the tumor versus
adjacent plot, even at low levels of signal.
Tumor and adjacent normal specimens came from the
same population of patients while donor specimens were
received from a different set of individuals. To examine
potential patient specific expression effects, the 60 tumors
and 63 adjacent normal cases were randomly segmented
into two groups, one group provided just tumor data and
the other just adjacent normal data and a scatter plot of
expression was generated. Since the segmentation of 63
cases can be performed in many different ways (permuta-
tions), the scatter analysis was performed 1000 times and
the correlation between the sample groups determined by
obtaining the mean correlation coefficient of the 1000
permutations. (Figure 2). In this analysis, the close corre-
lation in expression between tumor and adjacent normal
specimens persisted even when tumor and adjacent nor-
mal samples were taken from different patients.
To determine the statistical significance of the observed
differential expression between the three specimen
groups, SAM analysis was performed. From each compar-
ison (tumor v adjacent normal, tumor v donor and adja-
cent normal v donor), a SAM plot was generated and the
plots for the three comparisons were overlaid (Fig 3). The
diagonal line in Figure 3 represents no differential expres-
sion (identical observed and expected d values, for further
details see Materials and Methods) with points displaced
from the diagonal representing differential expression.
Figure 3 shows that each of the comparisons yields a dis-
tinct expression profile with donor v tumor exhibiting
more differential expression than adjacent normal v
tumor or donor v adjacent normal.
To further characterize the expression profiles from these
comparisons, differentially expressed gene lists were cre-
ated from each comparison by selecting genes whose d
values (for details, see Materials and Methods) exceed a
given threshold. False discovery rates (false positives/ total
number of genes in gene list) is no greater than 2.5% at
the deltas chosen for this analysis (Table 1).
At a delta of 2.0, when tumor expression is compared to
donor expression (Table 1), 474 differentially regulated
genes can be detected. At the same delta, when tumor
expression is compared to adjacent normals, only 92
Differential gene expression analysis of donor, tumor and adjacent normal protate cancer samples Figure 1
Differential gene expression analysis of donor, tumor and adjacent normal protate cancer samples. Scatter plot 
of MAS 5.0 derived tumor vs donor, adjacent normal v donor and tumor v adjacent normal samples. For each probe set, the 
mean MAS 5.0 expression values of all the samples in each specimen group was calculated. Scatter plot were constructed using 
the mean values for each specimen group.BMC Cancer 2005, 5:45 http://www.biomedcentral.com/1471-2407/5/45
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genes are differentially regulated between these two tis-
sues. Furthermore, at this delta, comparison of tumor
expression with adjacent normals does not yield any
genes up-regulated in tumors whereas the comparison
with donors demonstrates up-regulation of 121 genes.
Similarly at other deltas, approximately three times more
differentially regulated genes can be detected when
tumors are compared to donors than to adjacent normals.
As was discussed above, tumors and adjacent normal tis-
sues are obtained from the same patients and donor tis-
sues from a different sample population. Therefore the
larger gene expression differences between tumors and
donors may represent underlying patient specific (genetic,
demographic or handling) differences in patient (tumor
and adjacent normal) and donor prostates rather than
intrinsic differences between tumor, adjacent normal and
donor normal tissues. It is significant however, that SAM
analysis indicates that adjacent normals exhibit far less
differential regulation than tumors when both are com-
pared to donors. At all deltas (Table 1), tumors v donors
exhibit greater differential expression than adjacent nor-
mals v donor implying that tumors and adjacent normals
are not identical in gene expression. Therefore, tumor spe-
cific, and not patient specific, expression changes can
indeed by detected by comparing tumors to donor pros-
tates. Significantly, these results establish the presence of
unique gene expression profiles for prostate tissue from
donors, adjacent normals and tumors (see Fig 3) with
tumors differing more from donors than from adjacent
normals.
A potential limitation of our data is that donors span the
ages of 5 to 60 and all tumor patients are older than 40.
Therefore, the differential gene expression between
donors and patients may be due to age specific differences
in their prostates. To examine this, we segmented the
donors into different age groups and compared only the
40 to 60 year old donors with tumors of the same age
group. Although the number of cases in the study were
small, the expression pattern observed in this age matched
analysis is identical (data not shown) to that when all
donors are included suggesting that potential age related
differences in donor prostates do not contribute to the
results of the donor v tumor analysis.
GO annotation of differential gene expression
We examined the gene lists produced by SAM analysis of
tumor, adjacent normal and donor tissue with two objec-
tives: 1) to identify and functionally annotate some of the
genes that contribute to the unique expression signatures
of these tissues and 2) to determine whether adjacent nor-
mals or donors are the more appropriate baseline tissue
for detecting differentially expressed genes in tumors.
Functional annotation and comparison of the gene lists
was performed using Gene Ontology terms [22], for bio-
logical processes and Affymetrix's Gene Ontology Mining
Tool http://www.affymetrix.com.
When donors are used as the baseline for comparison,
tumors exhibit up-regulation of proliferation related
genes including transcription factors, signal transducers
and growth regulators (see additional file 1). This list
includes putative oncogenes, signal transducers and
growth regulators. Some of the most up-regulated genes
are v-fos, jun B, jun D, c-src tyrosine kinase, FGF receptor acti-
vating protein, immediate early protein and  early growth
response 1. The most down-regulated genes in tumors
include those involved in immune response and signal
transduction. Some of the genes in this list are the inter-
feron induced transmembrane proteins, Duffy blood group
antigen  and  tumor necrosis factor. In contrast, when
Regression analysis of permuted donors, adjacent normal and  tumor samples Figure 2
Regression analysis of permuted donors, adjacent 
normal and tumor samples. The 60 tumors and 63 adja-
cent normal tissues were segmented so that tumors and 
adjacent normal samples in each comparison were selected 
from different patients. The resulting tumor and adjacent 
normal samples were then subjected to regression analysis. 
Donor v tumor, donor v adjacent normal and adjacent nor-
mal comparisons were performed. Since the segmentation 
can be performed in many different ways, the analysis was 
performed 1000 times. The mean correlation coeifficient and 
standard deviation from each of these comparisons were 
plotted as box plots.BMC Cancer 2005, 5:45 http://www.biomedcentral.com/1471-2407/5/45
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adjacent normal tissue is used as the baseline for compar-
ison, tumor tissue exhibits far fewer differentially
expressed genes and the genes themselves are less compel-
ling. The list up regulated genes is dominated by ribos-
omal proteins and metabolic enzymes, while the down-
regulated list includes muscle related genes such as tropo-
mysin, actin and actinin.
When expression in adjacent normal is compared to
donors, an up-regulation pattern remarkably similar to
tumors is seen (additional file 1). Adjacent normals also
Overlayed SAM plots (for details, see Materials and Methods) from the donor v tumor, donor v adjacent normal and tumor v  adjacent normal analyses Figure 3
Overlayed SAM plots (for details, see Materials and Methods) from the donor v tumor, donor v adjacent nor-
mal and tumor v adjacent normal analyses. Each of the SAM plots was overlayed to direct comparison of the plots. The 
diagonal line represents no differential gene expression where the observed d value equals the expected d value after 1000 
permutations of the class labels. Genes that are differentially expressed are displaced from the diagonal (greater than 0 for up 
regulation and less than 0 for down regulation). Genes that are more differentially expressed are more displaced from the diag-
onal than those that are closer to the diagonal. For each of the comparisons, a plot is generated from the d values of the 12625 
probe sets in the two specimen groups. Red = donor v tumor plot; green = adjacent normal v tumor plot; black = adjacent 
normal v donor plot.BMC Cancer 2005, 5:45 http://www.biomedcentral.com/1471-2407/5/45
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exhibit up-regulation of putative oncogenes, signal trans-
ducers and growth regulators with an almost 70% overlap
of the 50 and 100 most up-regulated genes in tumors and
adjacent normals, respectively. Similarly there is almost
60% overlap between the most down-regulated genes in
tumors and adjacent normals that includes genes involved
in immune response.
The biological processes regulated in tumors and adjacent
normals were also studied using Affymetrix's Gene Ontol-
ogy Mining tool. The up regulated gene lists obtained at a
SAM delta of 2.0 (Table 1) were uploaded to the tool and
the resulting annotations examined. Comparison of
tumor gene expression to donor expression reveals up-reg-
ulation of genes involved in a number of biological proc-
esses (Figure 4a). Amongst these are genes involved in
apoptosis, cell cycle, cell proliferation, immune response,
protein phosphorylation, protein biosynthesis and tran-
scription. A subset of these including genes involved in
immune response and transcription are also up-regulated
in adjacent normals (Figure 4b). In contrast when tumor
expression is compared to adjacent normals, up-regula-
tion of majority of these processes, except protein metab-
olism, is not detected (Figure 4c).
Two important conclusions can be derived from the gene
annotations, 1) though there are large number of genes
regulated in tumors, there is a relatively small subset of
genes including oncogenes and signal transducers that are
highly regulated in both adjacent normal and tumor tis-
sues and 2) regulation of a number of potentially impor-
tant biological processes in tumors can be detected from
using donors as the baseline tissues. The common regula-
tion of oncogenes, signal transducers and immune
response genes in adjacent normals is a striking result in
that it suggests that adjacent normal tissue although
appearing morphologically normal, undergo gene expres-
sion changes that may be important in tumorigenesis or
as a reaction to tumor. Since these genes are regulated in
both tumor and adjacent normal, they are not picked up
on a direct comparison of the two tissues. While it is pos-
sible that donors are different from both adjacent normals
and tumors due to processing artifacts – the tumor and
adjacent tissues were taken at surgery and donors at har-
vesting – it is unlikely that the large differences seen in
donor v tumor are all due to processing differences. This
issue is examined further in the discussion section.
The up regulation of proliferation markers in both adja-
cent normals and tumors coupled with the result that
more differential regulation is detected when tumors are
compared to donors than to adjacent normals suggests
that donor prostates may be the more appropriate tissue
for expression studies. Regulation of critical of biological
processes and pathways may remain undetected if tissue
adjacent to tumors is used for comparison.
Discussion
There is a growing interest in the use of high throughput
microarray analysis for the molecular reclassification of
diseases. This interest appears to be well founded, as many
groups have reported consistent patterns of gene expres-
sion associated with pathologic phenotypes, clinical
behaviors and outcomes [4-11]. In the area of prostate
cancer numerous groups [23-29] have all reported signifi-
cant differential gene expression between histologic
tumor specimens and normal appearing prostate tissue
from patients with tumor present elsewhere in the pros-
tate. Recently, a group from our institution reported a 70
gene signature that may predict aggressiveness of prostate
cancer [12]. Comparison of the gene lists from published
data sets with the results of our tumor versus adjacent nor-
mal analysis is complicated by the heterogeneity in sam-
ples, analysis platforms and analysis methods.
Nevertheless, our study is qualitatively similar to other
studies in the expression profile of tumors compared to
adjacent normal tissue. A number of genes including hep-
sin, myc, fatty acid synthase SPARC1 and EBNA-2 coactiva-
tor show similar expression patterns across multiple
prostate cancer studies [30], and are also regulated in our
study.
Our donors did not have prostate cancer or prostatic
intraepithelial neoplasia (PIN) identified in their prostate
and as such are good candidates for "true normals". Dif-
ferential expression was much greater between tumor and
donor tissue than between tumor and adjacent normal.
Table 1: Differential gene expression in the tumor v donor, 
tumor v adjacent normal and adjacent normal v donor 
comparisons. The number of genes identified as differentially 
regulated at each delta (observed d value – expected d value; for 
details, see Materials and Methods) are shown. Also, shown are 
the number of up and down regulated genes at each delta. For 
each of these deltas, the false discovery rate was no greater than 
2.5%.
Delta 3.0 Delta 2.0 Delta 1.56
Tumor v Donor 65 474 928
Up Regulated 10 121 305
Down Regulated 55 353 623
Tumor v Adjacent Normal 09 2 3 8 2
Up Regulated 0 58
Down Regulated 92 324
Adjacent Normal v Donor 12 86 254
Up Regulated 5 25 63
Down Regulated 7 61 191BMC Cancer 2005, 5:45 http://www.biomedcentral.com/1471-2407/5/45
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The fact that tumor and adjacent specimens come from
the same patients could possibly explain this difference
but this was ruled out by our analysis. Another possibility
is that tissue handing and processing differences could
account for some or all of the differential expression seen
when donor tissue is use as a baseline. In fact, data in the
literature does suggest that tissue processing could effect
the expression of genes such as fos, jun and egr in prostate
tissue [29]. However, the same literature indicates that the
effect warm ischemic time is limited to specific genes and
in general, involves less than 1% of the regulated genes
[29]. Our studies emphasize the need for documentation
and quality of all experimental processing steps, from
sample acquisition to sample hybridization, in order to
completely characterize gene expression differences
between prostate donors, tumors and normal tissue adja-
cent to tumors.
In our experiment, tumor and adjacent normal specimens
where taken from the same prostates and handled the
same way. If differences in patient and donor tissue han-
dling was the major issue driving differential expression in
the tumor v donor and adjacent normal v donor compar-
isons, one would expect tumor v donor and adjacent nor-
mal to result in very similar expression profiles. However,
we have shown that tumor v donor exhibits far greater dif-
ferential expression than adjacent normal v donor (see
Results). Furthermore, the differentially expressed genes
Gene Ontology annotation of differentially expressed gene lists Figure 4
Gene Ontology annotation of differentially expressed gene lists. The fifty most upregulated genes from the donor v 
tumor, adjacent normal v tumor and tumor v adjacent normal comparisons were uploaded to Affymetrix's Gene Ontology 
Mining Tool, a, donor v tumor; b, donor v adjacent normal; c adjacent normal v tumor; The annotations is presented as a hier-
archy of terms, from general to most specific terms (from left to right). The numbers in parenthesis indicate the number of 
genes that are annotated with the term. In all of the analysis, annotation of all the submitted probe sets is not achieved. Typi-
cally, annotation exists for approximately 60% of the probe sets.
A.
B.
C.BMC Cancer 2005, 5:45 http://www.biomedcentral.com/1471-2407/5/45
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seen in both tumor and adjacent normal include proto-
oncogene and transcription factors that one might ration-
ally expect to see in expectation of or in response to a local
tumor. Therefore, while the possibility that some expres-
sion changes are due to differences in tissue handling can-
not be formally ruled out, it is unlikely that the large and
specific differences we observe in tumor v donor, tumor v
adjacent normal and adjacent normal v donor are entirely
due to processing differences. Clearly additional studies,
including examination of patient process specimens that
do not host prostate cancer (such as cystoprostatectomy
for bladder cancer or prostates removed for benign hyper-
trophy) to examine this process further.
The most important finding from our analysis is the
potential importance of the donor specimens and the pos-
sibility that a field effect exists around prostate tumors,
resulting in significant molecular changes in histologi-
cally normal appearing tissue adjacent to prostate cancer.
Significantly, evidence for such malignancy associated
changes have been presented in other organs such as the
cervix, bladder and breast [31-33]
Furthermore, a variety of methods such as chromosomal
analysis [13], SAGE [14], ploidy analysis [15,16] have
shown molecular abnormalities in normal appearing
prostate adjacent to tumor. Image analysis has also been
employed to identify consistent changes in "normal
appearing" prostate tissue adjacent to tumor [17,18]. In
one study cases of prostatic adenocarcinoma was consist-
ently detected by examining histologically normal tissue
using high-resolution image cytometry [18], and in
another, combined highly sensitive and discriminating
Fourier transform-infrared spectroscopy with statistical
analysis was used to detect damaged DNA in normal
appearing prostate tissue adjacent to cancer [34].
In expression analysis, while most published prostate
studies have used adjacent normals as the baseline tissue,
Dhansekaran [23], used both commercially available
pooled donor normal tissue and adjacent normal tissue
and noted differences in expression profile between the
two specimen types. Genes that were differentially
expressed in adjacent normals when compared to the
pooled donor normals included signal transducers and
transcription factors; and expression of these genes in
adjacent normals was attributed to a field effect around
tumors. Similarly, Yu [12] have noted dysregulation of
selected genes in both adjacent normals and tumors when
compared to donors. Prakash [27], found that gene
expression in asymptomatic benign prostatic hyperplasia
adjacent to tumors was different from asymptomatic BPH
or symptomatic BPH not associated with tumors. The
unique expression signature of BPH next to tumors
included fos, jun, immediate early genes and this list was
remarkably similar to the most up-regulated genes in the
adjacent normals tissue in our study (see adjacent normal
v donor, additional file 1).
Finally, within archives of the University of Pittsburgh
Pathology Tissue Bank, there was a donor prostate, which
was found to harbor prostate cancer. When run on the
Affymetrix arrays, the tumor classified with the tumors
samples rather than the donor samples. Although this is
clearly no more than an anecdotal event, it is an interest-
ing finding.
Though microarray technology represents a major
advance and provides a powerful tool for high-through-
put expression analysis, the most effective use of this tech-
nology requires careful consideration of baseline normal
tissue. Our results here emphasize the need for careful
examination of what constitutes normal tissue and the
importance of future studies to fully characterize normal
appearing tissue adjacent to prostate cancers.
Conclusions
Prostate tumor tissue, histologically normal tissue adja-
cent to tumors and donor normal prostate tissue exhibit
unique gene expression profiles with tumor and adjacent
normal profiles more similar to each other than to the
donors. These results suggest that normal appearing tissue
around prostate tumors may also be undergoing tumor
related changes and that careful characterization of these
different tissues is necessary to understand molecular
changes in leading up to prostate cancer.
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